21 June 2022

Within Screen4Care, an Innovative Medicines Initiative (IMI 2 JU), researchers are investigating medical specialists’ understanding, experience and attitudes regarding the application of machine learning (ML) in the diagnostic process of rare diseases. We are specifically focusing on the European Reference Networks (ERN) members as leading rare disease experts at international level.

Input of EURO-NMD members on this specific issue would be particularly important and could help shape the future implementation of ML in the field of rare diseases in the EU. Therefore,we invite EURO-NMD medical members to participate in this brief online survey: https://s4c.raredis.org/319413?lang=en

Please, note that participation in this survey is equally encouraged even if medical professionals have not yet gathered experience with Machine Learning tools.

Thank you !

What is Screen4Care?

Screen4Care offers an innovative research approach to accelerate rare disease diagnosis, which is based on two central pillars: genetic newborn screening and digital technologies. People living with rare diseases often find themselves on a burdensome diagnosis journey, enduring on average eight years of inconclusive consultations and possible misdiagnoses, leading to ineffective treatments and inefficient healthcare resource utilisation.

Click to Read More

The ERNs are co-funded by the
European Union (Health Programme and CEF)

EU Commission

“EURO-NMD is one of the 24 European Reference Networks (ERNs) approved by the ERN Board of Member States. The ERNs are co-funded by the European Union (Health Programme and CEF).
For more information about the ERNs and the EU health strategy,
please visit ec.europa.eu/health/ern